A Study of PY314 in Subjects With Advanced Solid Tumors

ABSTRACT: This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including pembrolizumab, if approved for that indication).

DISEASE(S): Lung Adenocarcinoma,Triple Negative Breast Neoplasms,Colorectal Cancer,Triple Negative Breast Cancer,Hormone Receptor/growth Factor Receptor-negative Breast Cancer,Breast Neoplasms,Breast Cancer,Ovarian Cancer,Gynecologic Cancer,Advanced Solid Tumor,Carcinoma, Renal Cell,Adenocarcinoma Of Lung,Renal Cell Carcinoma

PROVIDER: 2362511 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR